source
- New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in ChinaPlus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial: 🧠 Novo's Parkinson's cell therapy finds a biotech home: Novo Nordisk has found a home for an…Endpoints · 3mo ago↗ source
- Inhibrx says combo therapy shrank more tumors than Merck's Keytruda aloneSan Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more t…Endpoints · 3mo ago↗ source
- STAT+: Astellas treatment offers new hope to a devastated rare disease communityAlzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout